Osteonecrosis of the Femoral Head
8
2
3
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
1 terminated out of 8 trials
75.0%
-11.5% vs benchmark
13%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Triple-Modal Therapy in Early-Stage Femoral Head Osteonecrosis (TM-ONFH)
RAB001（LLP2A-Ale） in Healthy Subjects
Screening for Biomarkers of Osteonecrosis of the Femoral Head
A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head
Comparison of the Efficacy of Pericapsular Nerve Group Block Alone Versus Pericapsular Nerve Group Block Combined With Superior Cluneal and Superior Gluteal Nerve Blocks in Patients Undergoing Hip Surgery
Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis
Study on Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head
PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells